High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: A 10-year cohort study

BMC Infectious Diseases

Volumn 5, Issue , 2005, Pages

  Yu, Ming Lung ^a   Dai, Chia Yen ^a,b   Chen, Shinn Cherng ^a   Lee, Li Po ^a   Hsieh, Ming Yen ^a   Lin, Zu Yau ^a   Hsieh, Ming Yuh ^a   Wang, Liang Yen ^a   Tsai, Jung Fa ^a   Chang, Wen Yu ^a   Chuang, Wan Long ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHAN1 INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ALOPECIA; ANOREXIA; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DERMATITIS; DIARRHEA; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INSOMNIA; IRRITABILITY; KAPLAN MEIER METHOD; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTIVARIATE ANALYSIS; MYALGIA; NAUSEA; PRURITUS; RIGOR; SIDE EFFECT; SKIN DISEASE; TAIWAN; VIROLOGY; VIRUS LOAD; VOMITING;

EID: 25444506912     PISSN: 14712334     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-5-27     Document Type: Article

References (30)

1. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, Miller JK, Gerber MA, Sampliner RE: The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992, 327(27):1899-1905.
2. Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med 2001, 345(1):41-52.
3. Martinot-Peignoux M, Boyer N, Pouteau M, Castelnau C, Giuily N, Duchatelle V, Auperin A, Degott C, Benhamou JP, Erlinger S: Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J Hepatol 1998, 29(2):214-223.
4. Hwang SJ, Chan CY, Lu RH, Wu JC, Lee SD: Randomized controlled trial of recombinant interferon-alpha 2b in the treatment of Chinese patients with chronic hepatitis C. J Interferon Cytokine Res 1995, 15(7):611-616.
5. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP: Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996, 24(4):778-789.
6. Lindsay KL: Therapy of hepatitis C: overview. Hepatology 1997, 26(3 Suppl 1):71S-77S.
7. Carithers RLJ, Emerson SS: Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997, 26(3 Suppl 1):83S-88S.
8. Thevenot T, Regimbeau C, Ratziu V, Leroy V, Opolon P, Poynard T: Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update. J Viral Hepat 2001, 8(1):48-62.
9. Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, Nakamura A, Asada M, Kuroda H, Tanaka N, Arakawa Y, Omata M: Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology 1997, 113(2):558-566.
10. Yu ML, Chuang WL, Dai CY, Chen SC, Lin ZY, Hsieh MY, Wang LY, Chang WY: Clinical evaluation of the automated COBAS AMPLICOR HCV MONITOR test version 2.0 for quantifying serum hepatitis C virus RNA and comparison to the quantiplex HCV version 2.0 test. Journal Of Clinical Microbiology 2000, 38(8):2933-2939.
11. Hakozaki Y, Shirahama T, Katou M, Nakagawa K, Oba K, Mitamura K: A controlled study to determine the optimal dose regimen of interferon-alpha 2b in chronic hepatitis C. Am J Gastroenterol 1995, 90(8):1246-1249.
12. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981, 1(5):431-435.
13. Okamoto H, Tokita H, Sakamoto M, Horikita M, Kojima M, Iizuka H, Mishiro S: Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol 1993, 74(Pt 11):2385-2390.
14. Yu ML, Chuang WL, Chen SC, Lin ZY, Hsieh MY, Wang LY, Chang WY: Clinical application of the Quantiplex HCV RNA 2.0 and Amplicor HCV Monitor assays for quantifying serum hepatitis C virus RNA. Journal Of Clinical Pathology 1999, 52(11):807-811.
15. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS: Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282(5386):103-107.
16. Layden TJ: Principles of interferon induction therapy. Am J Med 1999, 107(6B):71S-73S.
17. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, Frezza M, Noventa F, Pontisso P, et al.: Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group. Hepatology 1995, 22(3):700-706.
18. Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region. Core Working Party for Asia-Pacific Consensus on Hepatitis B and C. J Gastroenterol Hepatol 2000, 15(8):825-841.
19. EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. J Hepatol 1999, 31 Suppl 1:3-8.
20. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, Payen JL, Sajus M, Costa JM: A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 1995, 332(22):1457-1462.
21. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, Areias J, Auperin A, Benhamou JP, Degott C, Erlinger S: Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997, 127(10):875-881.
22. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H, Omata M: Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000, 132(7):517-524.
23. Larghi A, Tagger A, Crosignani A, Ribero ML, Bruno S, Portera G, Battezzati PM, Maggioni M, Fasola M, Zuin M, Podda M: Clinical significance of hepatic HCV RNA in patients with chronic hepatitis C demonstrating long-term sustained response to interferon-alpha therapy. J Med Virol 1998, 55(1):7-11.
24. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339(21):1485-1492.
25. Yu ML, Chuang WL, Chen SC, Dai CY, Hou C, Wang JH, Lu SN, Huang JF, Lin ZY, Hsieh MY, Tsai JF, Wang LY, Chang WY: Changing prevalence of hepatitis C virus genotypes: Molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a Tertiary Referral Center in Taiwan. Journal of Medical Virology 2001, 65(1):58-65.
26. Kao JH, Lai MY, Chen PJ, Chen DS: Probable reinfection with hepatitis C virus in a chronic hepatitis C patient with a sustained response to combination therapy. J Formos Med Assoc 2001, 100(12):824-828.
27. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999, 131(3):174-181.
28. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358(9286):958-965.
29. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FLJ, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347(13):975-982.
30. Keating GM, Curran MP: Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 2003, 63(7):701-730.